Biological affinity based delivery systems
OwnerAlyssa Panitch, Brandon Sealinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions for drug delivery, comprising a polymer network; a plurality of polysaccharide binding (PB) polypeptides, wherein the plurality of PB polypeptides are covalently bound to the polymer network, but wherein the PB polypeptides do not serve to covalently cross-link the polymer network; and negatively charged polysaccharides non-covalently bound to the plurality of PB polypeptides; as well as methods for making and using the compositions.
Claims27
A composition comprising:
- a) a polymer network;
- b) a plurality of polysaccharide binding (PB) polypeptides, wherein the plurality of PB polypeptides are covalently bound to the polymer network, but wherein the PB polypeptides do not serve to covalently cross-link the polymer network;
- and
- c) negatively charged polysaccharides non-covalently bound to the plurality of PB polypeptides.
A method for making a composition, comprising:
- a) covalently linking a polymer to a PB polypeptide under conditions that inhibit crosslinking of the polymer by the PB polypeptide;
- and
- b) contacting the polymer-PB polypeptide complex with negatively charged polysaccharides under conditions that permit non-covalent interaction between the PB polypeptide and the negatively charged polysaccharides.
A method for drug delivery, comprising delivering therapeutics that elute from a heparin affinity column at an NaCl concentrations of 150 mM or more from a drug delivery device that comprises a polymer, a PB polypeptide covalently bound to the polymer, and a negatively charged polysaccharide bound to the PB polypeptide.
Dependencies are inferred from the claim text.